September 30, 2016
The Nuclear Science Advisory Committee (NSAC) is meeting this week to review the progress of the National Nuclear Security Administration’s (NNSA) Molybdenum-99 (Mo-99) program. Scheduled to occur September 29-30th in Bethesda, Maryland, the NSAC Mo-99 meeting is Congressionally mandated to ensure the NNSA is taking adequate measures to enact AMIPA and ensure a sustainable, domestic source of Mo-99 is available when the National Research Universal (NRU) reactor in Canada ceases commercial production of Mo-99 on October 31, 2016.
At the NSAC meeting, committee members will hear updates from various stakeholders involved in the production of Mo-99. On the first day of the meeting, NNSA will update the committee on the status of its cooperative agreement projects and discuss any developments that have occurred since NSAC’s 2015 recommendations to the NNSA. Additionally, the committee will hear directly from NNSA’s cooperative agreement partners (SHINE Medical Technologies, NorthStar Medical Radioisotopes, and General Atomics – MURR and Nordion) on their partnership with the NNSA and the risks they are facing in producing Mo-99. The Department of Energy will present the status of the Uranium Lease and Take-Back Program.
On the second day of the conference, the Organization for Economic Co-Operation and Development (OECD) will present its Mo-99 supply and demand projections. Later, the NSAC will receive input from Mo-99 stakeholders and members of the public before providing an opportunity for open discussion. Among the stakeholders attending to present comments is SNMMI representative Fred Fahey, DSc, FSNMMI, FACR, FAAPM, past president of SNMMI, who serves on the NSAC Committee.
Read the full NSAC meeting agenda here.
Lantheus has published a letter to its customers explaining the steps they have taken to secure the supply of Mo-99 in preparation for the transition away from NRU.